Mirum Pharmaceuticals to Present at SVB Leerink 11th Annual Global Healthcare Conference
Details:
Presentation link
Visit the Investors and Media section on Mirum’s website for additional information.
About
Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases affecting children and adults. Maralixibat (LIVMARLI), an oral ileal bile acid transporter (IBAT) inhibitor, is currently being evaluated in clinical trials for pediatric liver diseases and includes the MARCH Phase 3 study for progressive familial intrahepatic cholestasis (PFIC) and the EMBARK Phase 2b study for patients with biliary atresia. In addition, Mirum has an expanded access program open in
Mirum has submitted a Marketing Authorization Application to the
Mirum’s second investigational treatment, volixibat, also an oral IBAT inhibitor, is being evaluated in three potentially registrational studies including the OHANA Phase 2b study for pregnant women with intrahepatic cholestasis of pregnancy, VISTAS Phase 2b study for adults with primary sclerosing cholangitis, and the VANTAGE Phase 2b study for primary biliary cholangitis.
Follow Mirum on Twitter, Facebook, LinkedIn and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220209005460/en/
Mirum Contacts:
Media:
media@mirumpharma.com
Investors:
ir@mirumpharma.com
ir@mirumpharma.com
Source: